Home > Healthcare > Medical Services > gene therapy clinical trial services market
Get a free sample of Gene Therapy Clinical Trial Services Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Gene Therapy Clinical Trial Services Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The gene therapy clinical trial services industry is characterized by rapid growth and innovation, driven by increasing investment in R&D, rising prevalence of genetic disorders, and advancements in biotechnology. Major service providers focus on offering a range of services such as regulatory consulting, patient recruitment, and data management. Additionally, collaborations between industry and academia, along with supportive regulatory frameworks, contribute to a dynamic market landscape with significant opportunities for growth and advancement in gene therapy treatments.
Some of the prominent players operating in the gene therapy clinical trial services industry include:
The gene therapy clinical trial services market size was valued at USD 1.1 billion in 2023 and is estimated to grow at 9.2% CAGR from 2024 to 2032, attributed to the global rise in genetic disorders and chronic diseases.
The pharmaceutical & biotechnology companies end-use segment in the market may record USD 1.1 billion in revenue by 2032, due to their substantial R&D investments.
Asia Pacific gene therapy clinical trial services market size will grow at 9.6% CAGR between 2024 and 2032 due to increasing healthcare expenditure.
Almac Group, Catalent Biologics, Charles River Laboratories International, Inc., ICON plc, IQVIA Biotech, Labcorp Drug Development, Medpace Holdings, Inc., Novotech, and Parexel International (MA) Corporation among others.